NASDAQ:TPST Tempest Therapeutics (TPST) Stock Price, News & Analysis $1.24 -0.01 (-0.80%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.23▼$1.3150-Day Range$0.96▼$2.2352-Week Range$0.17▼$9.77Volume370,651 shsAverage Volume1.58 million shsMarket Capitalization$31.26 millionP/E RatioN/ADividend YieldN/APrice Target$20.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Tempest Therapeutics alerts: Email Address Tempest Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,573.4% Upside$20.75 Price TargetShort InterestBearish10.22% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$966,799 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.56) to ($1.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.96 out of 5 starsMedical Sector548th out of 910 stocksPharmaceutical Preparations Industry253rd out of 426 stocks 3.5 Analyst's Opinion Consensus RatingTempest Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTempest Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Tempest Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.22% of the float of Tempest Therapeutics has been sold short.Short Interest Ratio / Days to CoverTempest Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tempest Therapeutics has recently increased by 4.46%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldTempest Therapeutics does not currently pay a dividend.Dividend GrowthTempest Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TPST. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Tempest Therapeutics this week, compared to 2 articles on an average week.Search Interest17 people have searched for TPST on MarketBeat in the last 30 days. This is an increase of 750% compared to the previous 30 days.MarketBeat Follows6 people have added Tempest Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tempest Therapeutics insiders have sold 866.79% more of their company's stock than they have bought. Specifically, they have bought $100,001.00 in company stock and sold $966,799.00 in company stock.Percentage Held by InsidersOnly 3.27% of the stock of Tempest Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 22.52% of the stock of Tempest Therapeutics is held by institutions.Read more about Tempest Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Tempest Therapeutics are expected to grow in the coming year, from ($1.56) to ($1.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tempest Therapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tempest Therapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTempest Therapeutics has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Tempest Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsWhat is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. About Tempest Therapeutics Stock (NASDAQ:TPST)Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.Read More TPST Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TPST Stock News HeadlinesAugust 13, 2024 | insidertrades.comTempest Therapeutics, Inc. (NASDAQ:TPST) Major Shareholder Versant Venture Capital Vi, L. Sells 387,999 SharesSeptember 5 at 8:00 AM | globenewswire.comTempest to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …August 23, 2024 | globenewswire.comTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 21, 2024 | finance.yahoo.comTempest set to storm the HCC landscape with promising Phase II amezalpat dataAugust 21, 2024 | finance.yahoo.comTempest Announces the Appointment of Troy M. Wagner as Vice President of Quality AssuranceAugust 18, 2024 | uk.investing.comScotiabank maintains a target on Tempest Therapeutics stockAugust 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tempest Therapeutics Amidst Promising Phase 3 Outlook and Funding UncertaintiesSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …August 15, 2024 | globenewswire.comTempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular CarcinomaAugust 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tempest Therapeutics Amid Strong Clinical Results and Solid FinancialsAugust 9, 2024 | investorplace.comTPST Stock Earnings: Tempest Therapeutics Misses EPS for Q2 2024August 8, 2024 | globenewswire.comTempest Reports Second Quarter 2024 Financial Results and Provides Business UpdateJuly 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), CVS Health (CVS) and Tempest Therapeutics (TPST)June 20, 2024 | benzinga.comWhat's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?June 20, 2024 | investorplace.comWhy Is Tempest Therapeutics (TPST) Stock Up 45% Today?June 18, 2024 | globenewswire.comTempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular CarcinomaJune 7, 2024 | globenewswire.comTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive TPST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tempest Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TPST CUSIPN/A CIK1544227 Webwww.millendo.com Phone415-798-8589FaxN/AEmployees20Year Founded2012Price Target and Rating Average Stock Price Target$20.75 High Stock Price Target$47.00 Low Stock Price Target$8.00 Potential Upside/Downside+1,573.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,490,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-201.10% Return on Assets-78.32% Debt Debt-to-Equity Ratio0.12 Current Ratio2.17 Quick Ratio2.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.39 per share Price / Book0.89Miscellaneous Outstanding Shares25,210,000Free Float21,491,000Market Cap$31.26 million OptionableOptionable Beta-1.85 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Stephen R. Brady J.D. (Age 54)LLM, CEO, President & Director Comp: $923.24kMr. Nicholas Maestas (Age 43)VP of Strategy & Finance and Secretary Comp: $465.43kDr. Samuel Whiting M.D. (Age 58)Ph.D., Executive VP & Chief Medical Officer Comp: $667.65kMr. Justin Trojanowski (Age 36)Corporate Controller, Treasurer & Principal Accounting Officer Ms. Lindsay YoungHead of Human ResourcesDr. Sharon Sakai Ph.D.RAC, Head of Regulatory & QualityMore ExecutivesKey CompetitorsAnixa BiosciencesNASDAQ:ANIXCardiff OncologyNASDAQ:CRDFInvivydNASDAQ:IVVDCervoMedNASDAQ:CRVOAdlai NortyeNASDAQ:ANLView All CompetitorsInsiders & InstitutionsVersant Venture Capital Vi, L.Sold 387,999 sharesTotal: $426,798.90 ($1.10/share)Dimensional Fund Advisors LPBought 25,084 shares on 8/9/2024Ownership: 0.113%Versant Venture Capital Vi, L.Sold 400,000 sharesTotal: $540,000.00 ($1.35/share)Stephen R BradyBought 35,000 shares on 7/3/2024Total: $73,850.00 ($2.11/share)Samuel WhitingBought 4,672 shares on 7/2/2024Total: $9,951.36 ($2.13/share)View All Insider TransactionsView All Institutional Transactions TPST Stock Analysis - Frequently Asked Questions How have TPST shares performed this year? Tempest Therapeutics' stock was trading at $4.40 at the start of the year. Since then, TPST shares have decreased by 71.8% and is now trading at $1.24. View the best growth stocks for 2024 here. How were Tempest Therapeutics' earnings last quarter? Tempest Therapeutics, Inc. (NASDAQ:TPST) posted its earnings results on Thursday, August, 8th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.05. When did Tempest Therapeutics' stock split? Shares of Tempest Therapeutics reverse split on Friday, June 25th 2021. The 1-15 reverse split was announced on Friday, June 25th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 28th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Tempest Therapeutics' major shareholders? Tempest Therapeutics' top institutional investors include Dimensional Fund Advisors LP (0.11%). Insiders that own company stock include Thomas Woiwode, Versant Venture Capital Vi, L, Stephen R Brady, Justin Trojanowski, Samuel Whiting and Thomas W Dubensky. View institutional ownership trends. How do I buy shares of Tempest Therapeutics? Shares of TPST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TPST) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempest Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tempest Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
